PharmaTher sets out CraftMake placement plan, renames platform M3DICINES
The Toronto-based company targets up to 50 pharmaceutical 3D printer placements in North America within 12 months
PharmaTher Holdings Ltd. has outlined plans to place up to 50 CraftMake pharmaceutical 3D printers across North America over the next 12 months, with initial orders expected in the fourth quarter of 2026. The Toronto-based company holds exclusive North American distribution rights to Craft Health Pte. Ltd.’s CraftMake platform and has renamed its PERSONALIZ3D platform M3DICINES.
The first placements are planned for PD Labs, a national 503A compounding pharmacy and PharmaTher’s U.S. Center of Excellence, and at an unnamed good manufacturing practice (GMP) contract manufacturer. Target sites include pharmacies, telehealth companies, hospitals, and research and government facilities, out of an estimated 10,000-plus in North America.
Each placement is being designed to generate system revenue plus recurring software, consumables and service revenue, according to the company. Craft Health was to supply the hardware, PD Labs to handle U.S. 503A compounding and research, and the contract manufacturer to cover U.S. Food and Drug Administration (FDA)-track products and contract development and manufacturing organization (CDMO) services. PharmaTher also plans white-label products and formulation licensing.
“Today we are setting out how we plan to turn our exclusive North American rights to CraftMake into a scalable business,” said Fabio Chianelli, Chairman and Chief Executive Officer of PharmaTher. “We are advancing proprietary products, and we plan to grow a network of placements and open our platform to partners.
“Each printer we place is designed to generate recurring revenue and add a node to a network that can support our commercial partners and help in a national emergency. We expect the model to reinforce itself, as each placement brings formulations, data and partners that can lead to the next.
“Over the next 12 months, we plan to place our first systems, launch our first products and apply for designations in our rare pediatric program. From there, we plan to expand into other ultra-rare diseases and bring back discontinued medicines that are no longer made at scale, working toward our goals of growing commercial sales and recurring revenue and achieving an FDA approval of a PharmaTher printed medicine.”
PharmaTher is preparing its first 503A products, including NAD+, glutathione and the peptides sermorelin and PT-141, for the fourth quarter of 2026, followed by a ketamine dissolvable tablet for telehealth in the first quarter of 2027.
The company is also targeting a new drug application for a 3D printed rare pediatric disease tablet in the fourth quarter of 2028, with orphan drug and rare pediatric disease designation applications planned for October 2026.



